Bloomberg Law: Privacy & Data Security brings you single-source access to the expertise of Bloomberg Law’s privacy and data security editorial team, contributing practitioners,...
By Jimmy H. Koo
The Federal Trade Commission’s data security enforcement action against now-defunct medical testing company LabMD Inc. is “repugnant to comprehensive healthcare regulation,” the company said in a March 9 court filing ( LabMD, Inc. v. FTC , 11th Cir., No. 16-16270, reply brief filed 3/9/17 ).
LabMD also challenged the commission’s interpretation of its enforcement authority under the FTC Act, telling the U.S. Court of Appeals for the Eleventh Circuit that the FTC’s interpretation of the statute “is directly at odds with Congress’s clear intent and is, in any event, unreasonable.”
Companies under the FTC’s jurisdiction—from internet giants Amazon.com Inc. and Facebook Inc. to smaller businesses such as LabMD—have struggled with what level of data security they must provide to convince the nation’s main data security and privacy enforcement agency that their efforts to protect personal data are reasonable.
In the absence of direct data security statutory or regulatory authority, the FTC has relied on the act’s Section 5, a catch-all prohibition against unfair and deceptive trade practices, to carry out data security compliance actions.
In its reply brief, LabMD said the commission failed to provide “ascertainable certainty of its interpretation” of “reasonable security” under Section 5. The commission hasn’t provided “meaningful guidance as to what specific security measures or approaches it believes” are required under Section 5, it said.
The company also reasserted its challenge against the FTC’s interpretation of “likely” and “substantial injury.” Likely doesn’t include low probability events, it said. The FTC, without any basis for assertion, equates “substantial injury” with the standard for “legally cognizable injury” required to sue in federal court, also known as Article III standing, LabMD said. If Congress wanted to equate substantial injury with legally cognizable injury, “it would have expressly adopted that test,” it said.
An FTC spokeswoman told Bloomberg BNA March 10 that the commission doesn’t “comment on pending litigation.”
Ropes & Gray LLP is representing LabMD.
To contact the reporter on this story: Jimmy H. Koo in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Donald Aplin at email@example.com
Full text of the reply brief is available at http://www.bloomberglaw.com/public/document/LabMD_Inc_v_Federal_Trade_Commission_Docket_No_1616270_11th_Cir_S/11.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)